THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

PP405 demonstrated significant hair density improvements in men with advanced hair loss, with 31% showing greater than 20% increase at 8 weeks compared to 0% in placebo group.

Humacyte's acellular tissue engineered vessel (ATEV) demonstrated superior functional patency compared to standard arteriovenous fistulas in high-risk hemodialysis patients with end-stage kidney disease.

Dr. Elizabeth Mittendorf, the 2026-2027 ASCO President-Elect, will focus on advancing multidisciplinary collaboration, broadening clinical trial access, and strengthening oncology workforce support during her presidency.

Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.

Mirvie's blood test successfully identified 91% of preterm preeclampsia cases in women over 35 without pre-existing conditions, using RNA signatures detectable at 17.5-22 weeks gestation.

Researchers at Mass General Brigham have repurposed foralumab, a monoclonal antibody nasal spray initially developed for multiple sclerosis, to target brain inflammation in Alzheimer's disease.

A randomized controlled trial reveals vitamin D supplementation helps maintain telomeres, protective chromosome caps that shorten during aging, effectively preventing nearly three years of biological aging.

Researchers at Mass General Brigham have developed AAV.CPP.16, an engineered virus that can deliver gene therapy to lungs and airways through a simple nasal spray, outperforming conventional vectors in efficiency and specificity.

Mass General Brigham researchers analyzed over 7,000 diabetes patients and found immediate statin therapy reduced heart attack and stroke risk by one-third compared to delayed treatment.

A retrospective analysis by Mass General Brigham and UCSF researchers found that glioblastoma patients taking gabapentin lived 4-6 months longer than those who didn't receive the medication.